Attached files
| file | filename |
|---|---|
| 8-K - BIOTIME, INC 8-K 6-30-2014 (OUM) - Lineage Cell Therapeutics, Inc. | form8k.htm |
Exhibit 16.1
July 7, 2014
Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549-7561
Ladies and Gentlemen:
We have read BioTime, Inc.’s statements included under Item 4.01 of its Form 8-K dated June 30, 2014, and are in agreement with the statements contained therein concerning our Firm in response to Item 304(a) of Regulation S-K.
Very truly yours,
/s/Rothstein Kass